Fig. 4: Cross-reactive type I antigen exposure protects mice from allergy.
From: Environmentally driven immune imprinting protects against allergy
a, Epitope profiling of IgG reactivity against indicated OVA proteins from cOVA-sensitized SPF (C57BL/6J) mice (n = 12). Each row represents one sample matched across OVA proteins. OVA proteins are ordered according to sequence conservation relative to cOVA. b, Experimental scheme for pre-sensitization type I immune polarization. SPF mice were subcutaneously injected with CFA emulsions containing OVA orthologues or without additional antigen on day 0. Three weeks later, mice were subcutaneously injected on the contralateral flank with cOVA adsorbed to alum. cOVA/alum injections were repeated one week later, serum samples were collected after five days, and mice were challenged intraperitoneally with cOVA for measurement of anaphylaxis.0 c,d, Maximal temperature decrease following systemic cOVA challenge (c) and cOVA-reactive serum antibodies of the indicated isotypes (d) (CFA qOVA: n = 9; otherwise, n = 10). e, Maximal temperature decrease as a function of combined cOVA-reactive IgG concentration divided by cOVA-reactive IgE concentration. f, Experimental scheme for post-sensitization type I immune polarization. SPF mice were subcutaneously injected with cOVA adsorbed to alum and three weeks later were subcutaneously injected on the contralateral flank with the indicated CFA preparation. Serum samples were collected after 12 days, and mice were challenged intraperitoneally with cOVA after a further two days. g,h, Maximal core temperature decrease following systemic cOVA challenge (g) and cOVA-reactive serum antibodies of the indicated isotypes (h) (CFA cOVA: n = 12; CFA qOVA: n = 15; CFA (no antigen): n = 14). One-way ANOVA with Tukey correction for multiple comparisons (c,d,g,h). Error bars represent s.d. NS, not significant. Data are pooled from two or more repeats of each experiment.
